Syros Pharmaceuticals (SYRS) Upgraded by Roth Capital to “Buy”

Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by equities research analysts at Roth Capital to a “buy” rating in a research note issued on Monday. The firm presently has a $12.00 price target on the stock. Roth Capital’s price target points to a potential upside of 54.64% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. HC Wainwright reaffirmed a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, August 8th. BidaskClub raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 31st. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Friday, August 10th. Cann reissued a “buy” rating and set a $26.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, August 7th. Finally, JMP Securities set a $33.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $19.00.

Shares of NASDAQ SYRS opened at $7.76 on Monday. The firm has a market capitalization of $261.16 million, a P/E ratio of -3.64 and a beta of 0.78. Syros Pharmaceuticals has a one year low of $6.25 and a one year high of $15.88.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Thursday, November 1st. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.02). The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million. As a group, analysts expect that Syros Pharmaceuticals will post -1.86 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Wedge Capital Management L L P NC acquired a new position in Syros Pharmaceuticals in the third quarter valued at about $731,000. Alps Advisors Inc. lifted its position in Syros Pharmaceuticals by 26.0% in the third quarter. Alps Advisors Inc. now owns 59,553 shares of the company’s stock valued at $709,000 after buying an additional 12,280 shares during the last quarter. Northern Trust Corp lifted its position in Syros Pharmaceuticals by 52.2% in the second quarter. Northern Trust Corp now owns 275,638 shares of the company’s stock valued at $2,814,000 after buying an additional 94,548 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Syros Pharmaceuticals by 36.8% in the second quarter. Bank of New York Mellon Corp now owns 70,592 shares of the company’s stock valued at $720,000 after buying an additional 19,005 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Syros Pharmaceuticals by 129.3% in the second quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock valued at $3,834,000 after buying an additional 211,696 shares during the last quarter. 60.74% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

See Also: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply